Professional Documents
Culture Documents
Requests for publications, or for permission to reproduce or translate WHO publications – whether for sale or
for noncommercial distribution – can be obtained from SEARO Library, World Health Organization, Regional
Office for South-East Asia, Indraprastha Estate, Mahatma Gandhi Marg, New Delhi 110 002, India (fax: +91 11
23370197; e-mail: searolibrary@who.int).
The designations employed and the presentation of the material in this publication do not imply the expression of
any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country,
territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines
on maps represent approximate border lines for which there may not yet be full agreement.
The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed
or recommended by the World Health Organization in preference to others of a similar nature that are not
mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital
letters.
All reasonable precautions have been taken by the World Health Organization to verify the information contained
in this publication. However, the published material is being distributed without warranty of any kind, either
expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no
event shall the World Health Organization be liable for damages arising from its use.
This publication does not necessarily represent the decisions or policies of the World Health Organization.
Printed in India
Photos courtesy of The Leprosy Mission England and Wales; Institute Lauro De Souza Lima, WHO collaborating centre;
Bauru-SP, Brazil; Damien Foundation Belgium; and Ed Hanley – photographer and videographer, Toronto, Canada.
Contributors................................................................................................................................v
Abbreviations.............................................................................................................................. vi
Foreword................................................................................................................................... vii
1. Introduction........................................................................................................................1
1.1 Achievements........................................................................................................... 2
1.2 Current leprosy situation........................................................................................... 3
1.3 Challenges................................................................................................................ 5
3. Guiding principles...............................................................................................................9
3.1 Responsibility of national governments and strengthening partnerships...................... 9
3.2 Sustaining expertise in leprosy................................................................................... 9
3.3 Quality leprosy services with children and women as the focus................................. 9
3.4 Participation of persons affected by leprosy in leprosy services................................ 10
3.5 Protection of human rights...................................................................................... 10
3.6 Focus on research to support leprosy control........................................................... 10
4. Strategic pillars..................................................................................................................11
4.1 Strengthen government ownership, coordination and partnership........................... 11
4.2 Stop leprosy and its complications........................................................................... 11
4.3 Stop discrimination and promote inclusion............................................................. 13
5. Implementation plans.......................................................................................................15
5.1 Regional and country implementation..................................................................... 15
5.2 Monitoring of targets and indicators globally and at country level............................ 15
5.3 Advocacy of Global Leprosy Strategy....................................................................... 15
5.4 Technical advisory bodies to the WHO Global Leprosy Programme......................... 16
6. References........................................................................................................................17
National Leprosy Programmes: Dr Safir Uddin Relief; Dr Wim van Brakel, Netherlands Leprosy
Ahmed, Bangladesh; Dr Rezia Begum, Bangladesh; Relief; Dr P. Vijayakumaran; Dr Marcos Virmond,
Dr Rosa Soares, Brazil; Dr Larissa Scholte, Brazil; International Leprosy Association; Dr Geoff Warne,
Dr Eliane Ignotti, Brazil; Dr Lay Sambath, Cambodia; The Leprosy Mission International;
Dr Yu Mei Wen, China; Dr Nestor Nietro, Colombia;
Dr Rigobert Abbet Abbet, Côte d’Ivoire; Dr Raisa Partner organizations: Dr Ann Aerts, Novartis
Castillo, Cuba; Dr Jean Mputu Luengo, Democratic Foundation; Dr M.A. Arif, ILEP India; Dr Sunil Anand,
Republic of Congo; Dr Sameeh Haridi, Egypt; The Leprosy Mission India Trust; Dr Edith Bahmanyar,
Dr Lelise Assebe, Ethiopia; Dr C.M. Agrawal, India; Novartis Foundation; Mr Mezemir Ketema Beyene,
Dr Anil Kumar, India; Dr K.S. Bhagotia, India; Dr Rita ALERT, Ethiopia; Dr David Blaney, US Centers for
Djupuri, Indonesia; Ms Erei Rimon, Kiribati; Dr Savanh Disease Control and Prevention; Sister Consilia,
Saypraseuth, Lao People’s Democratic Republic; Catholic Health Association of India; Mr John K.
Dr Andriamira Randrianantoandro, Madagascar; George, Fairmed, India; Ms Maria Globan, Victorian
Ms Fathimath Rasheeda, Maldives; Ms Caroline Infectious Diseases Reference Laboratory, Melbourne,
Jibas, Marshall Islands; Dr Edgar Martinez, Mexico; Australia; Dr P.K. Gopal, IDEA International; Mr Venu
Ms Stephanie Kapiriel, Federated States of Micronesia; Gopal, Association of People Affected by Leprosy,
Dr Olga Amiel, Mozambique; Dr Francisco Guilengue, India; Mr Tadesse Tesfaye Haile, ENAPAL Ethiopia;
Mozambique; Dr Than Lwin Tun, Myanmar; Dr Oke Dr S.K. Jain, National Centre for Disease Control,
Soe, Myanmar; Dr Basu Dev Pandey, Nepal; India; Ms P.K. Jayashree; Ms Katharina Jones,
Dr Moussa Gado, Niger; Dr Urhioke. Ochuko, ILEP; Dr Sanjay Mahendale, National Institute of
Nigeria; Mr Adebayo Peters, Nigeria; Dr Julio Correa, Epidemiology, India; Dr Takahiro Nanri, The Nippon
Paraguay; Dr Arturo Cunanan Jr, the Philippines; Foundation; Mr V. Narsapa, APAL India; Dr Anthony
Ms Gia Manlapig, the Philippines; Mr Oliver Merpeta, Samy, ALERT-India; Dr Sanjay Sarin, Foundation
Solomon Islands; Dr M.L.S. Nilanthie Fernando, Sri for Innovative New Diagnostics, India; Dr Vineeta
Lanka; Dr Mohamed Salah Altahir Alsamani, Sudan; Shankar, Sasakawa Memorial Health Foundation of
Dr Beatrice Mutayoba, United Republic of Tanzania; India; Ms Hiroe Soyagimi, Sasakawa Memorial Health
Dr Deusdedi V. Kamala, United Republic of Tanzania; Organization; Dr J. Subbanna, Lepra Health In Action;
Mr Tatsuya Tanami, The Nippon Foundation; Ms Yuko
Experts: Dr G. Rajan Babu, ILEP; Professor Emmanuelle Tani, The Nippon Foundation; Ms Jillian M. Tomlinson,
Cambau, National Reference Centre for Mycobacteria, Pacific Leprosy Foundation; Dr Bart Vander Plaetse,
Paris, France; Dr Hugh Cross, American Leprosy Novartis Foundation; Ms K. Yamaguchi, Sasakawa
Missions; Professor Paul Fine, London School of Memorial Health Foundation;
Hygiene and Tropical Medicine; Professor Zhang
Guocheng; Dr U.D. Gupta, Central JALMA Institute WHO: Dr Md. Reza Aloudal, WCO Afghanistan;
for leprosy and other mycobacterial diseases; Dr M.D. Dr Lin Aung , SEARO; Dr Awe Ayodele, WCO
Gupte; Dr Roch Johnson, Fondation Raoul Follereau; Nigeria; Dr Abate Mulugeta Beshah, WCO Ethiopia;
Dr Herman-Joseph S. Kawuma, German Leprosy Relief Dr Sumana Barua, GLP; Dr Erwin Cooreman, GLP;
Association; Dr P. Krishnamurthy; Dr Mallika Lavania, Dr Rui Paulo De Jesus, SEARO; Dr Dirk Engels, HQ;
The Leprosy Mission Community Hospital, Delhi; Dr Albis F. Gabrielli, EMRO; Dr Laura Gillini, GLP;
Professor Diana Lockwood, London School of Hygiene Dr Andrianarisoa S. Hermas, WCO Madagascar;
and Tropical Medicine; Dr Masanori Matsuoka; Dr Saurabh Jain, WCO India; Dr Ahmed J. Mohamed,
Professor R.K. Mutatkar, Centre for Health Research SEARO; Dr Stephen Lyons, HQ; Dr Ruben S.
and Development, India; Dr S.K. Noordeen; Professor Nicholls, PAHO/AMRO; Dr Nobuyuki Nishikiori,
Maria Leide W. Oliveira; Dr Vijay Kumar Pannikar; WPRO; Dr V.R.R. Pemmaraju, GLP; Dr Alexandre
Dr Paul Saunderson, American Leprosy Missions; Tiendrebeogo, AFRO.
Professor W.C. Smith, Aberdeen School of Medicine
and Dentistry; Mr Jan van Berkel, Netherlands Leprosy
Its goal is to further reduce the burden of (5) Incorporate specific interventions
leprosy at the global and the local level. The against stigma and discrimination due
strategy is structured around three pillars: to leprosy by establishing effective
collaboration and networks to address
(1) Strengthen government ownership, relevant technical, operational and
coordination and partnership social issues which will benefit persons
(2) Stop leprosy and its complications affected by leprosy. A significant
(measurable) reduction of stigma
and discrimination against persons
1 In view of fluctuating rates in small populations, this target
was not applicable to countries or jurisdictions with a
population of less than one million people 2 Paediatric cases include children below the age of 15
O
SY- REE
F
2020
INDICATORS
Zero disease target
Zero disability due to leprosy and local leprosy burden Rate of newly diagnosed leprosy patients with <1 per
visible deformities million
Zero stigma and discrimination Number of countries with legislation allowing
0
discrimination on basis of leprosy
2. Stop leprosy and its complications 3. Stop discrimination and promote inclusion
• Strengthening patient and community awareness on leprosy. • Promoting societal inclusion through addressing all forms of
discrimination and stigma.
• Promoting early case detection through active case-finding • Empowering persons affected by leprosy and strengthen their
(e.g. campaigns) in areas of higher endemicity and contact capacity to participate actively in leprosy services.
management.
• Involving communities in actions for improvement of leprosy
• Ensuring prompt start and adherence to treatment, including services.
working towards improved treatment regimens. • Promoting coalition-building among persons affected by leprosy
and encourage the integration of these coalitions and or their
• Improving prevention and management of disabilities.
members with other community-based organizations.
• Strengthening surveillance for antimicrobial resistance including • Promoting access to social and financial support services, e.g.
laboratory network. to facilitate income generation, for persons affected by leprosy
and their families.
• Promoting innovative approaches for training, referrals and
sustaining expertise in leprosy such eHealth. • Supporting community-based rehabilitation for people with
leprosy-related disabilities.
• Promoting interventions for the prevention of infection and
• Working towards abolishing discriminatory laws and promote
disease.
policies facilitating inclusion of persons affected by leprosy.
Strengthen government
ownership, coordination and
partnership
GOAL VISION
A LEPR O
W O RLD
y 202 0
R ed uce d le
Y-F R E
nb
pr
de
o s y b ur
213 899 94%
newly diagnosed patients were reported in of leprosy patients reported in 2014 were
2014, corresponding to a detection rate of notified in 13 countries: Bangladesh, Brazil,
3.0/100 000 population. Democratic Republic of Congo, Ethiopia, India,
Indonesia, Madagascar, Myanmar, Nepal,
Nigeria, the Philippines, Sri Lanka and the
United Republic of Tanzania.
175 554 14 110
patients were on treatment at the end of 2014 new cases were detected with G2D,
corresponding to a point prevalence of 0.25 corresponding to 6.6% of the total number
per 10 000 population. of newly diagnosed patients and to a rate of
2.0 cases per million.
3 Reports were compiled from countries in the WHO African, Americas, Eastern Mediterranean, South-East Asia and Western Pacific
Regions
18 869 61%
new patients detected and reported in 2014 of the patients were multibacillary (MB) cases
were children, corresponding to 8.8% of the of leprosy
total number of reported patients.
1312
relapses were reported from 46 countries.
Table 1: Registered prevalence at end of 2014 and number of new cases detected during 2014,
by WHO Region